Aurinia Pharmaceuticals (AUPH) vs Harmony Biosciences (HRMY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 50.4% versus a gain of 40.7%. Over five years, HRMY leads with a +0.5% price change compared with -21.1% for AUPH. Harmony Biosciences is the larger company by market cap ($2.35 billion vs $2.22 billion), about 1.1 times the size.
On valuation, Harmony Biosciences trades at a lower forward P/E (5.8x vs 15.6x for Aurinia Pharmaceuticals). Aurinia Pharmaceuticals converts more of its revenue into profit, with a net margin of 101.5% versus 18.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | HRMY |
|---|---|---|
| Share price | $16.65 | $40.28 |
| Market cap | $2.22B | $2.35B |
| 1-day change | +2.65% | +1.72% |
| YTD return | +1.69% | +7.64% |
| 1-year return | +40.68% | +50.41% |
| 5-year return | -21.15% | +0.51% |
| P/E ratio (TTM) | 7.30 | 12.99 |
| Forward P/E | 15.61 | 5.75 |
| EPS (TTM) | $2.28 | $3.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | $868.45M |
| Revenue growth (YoY) | +20.38% | +21.51% |
| Net income (latest FY) | $287.20M | $158.69M |
| Gross margin | 88.46% | 77.16% |
| Operating margin | 37.06% | 24.00% |
| Net margin | 101.47% | 18.27% |
| 52-week high | $19.25 | $43.49 |
| 52-week low | $10.90 | $25.52 |
| Distance from 52-week high | -13.51% | -7.38% |
| Analyst consensus | none | buy |
| Avg. price target upside | +7.27% | +18.27% |
| Average volume | 977.05K | 892.55K |
| Shares outstanding | 133.05M | 58.24M |
| Employees | 128 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Harmony Biosciences trades at a higher earnings multiple (13.0x vs 7.3x trailing P/E).
- Aurinia Pharmaceuticals is more profitable, keeping 101.5 cents of every revenue dollar as net income versus 18.3 cents for Harmony Biosciences.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
AUPH vs HRMY FAQ
Which is bigger, Aurinia Pharmaceuticals or Harmony Biosciences?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $2.35B compared with $2.22B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or HRMY?
HRMY returned +50.41% over the past 12 months, compared with +40.68% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AUPH or HRMY?
AUPH has the lower trailing P/E at 7.3, versus 13.0 for HRMY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Aurinia Pharmaceuticals and Harmony Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.